GlassScriptPhysician profile
Chukwuma O Ndibe
NPI 1881824266
$10,657.60
in general payments reported to CMS, 2019-2025
70 companies · $1,956 in 2025
The $1,956 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $1,557 · 2021: $940 · 2022: $1,892 · 2023: $2,191 · 2024: $1,569 · 2025: $1,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,600 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,599.53 |
| Education | $117.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,023.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $712.11 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $620.06 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $609.06 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Eisai INC. | $551.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $457.72 | 2019-2025 | Lynparza |
| Amgen INC. | $415.60 | 2019-2023 | Lumakras |
| Genentech USA, INC. | $406.48 | 2022-2025 | Polivy, Tecentriq, Rozlytrek |
| Pfizer INC. | $369.74 | 2021-2025 | |
| Lilly USA, LLC | $342.74 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $313.28 | 2020-2025 | Darzalex, Imbruvica, Talvey |
| Seagen INC. | $300.31 | 2019-2023 | Padcev, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $292.93 | 2019-2023 | Imbruvica |
| Incyte Corporation | $264.83 | 2020-2025 | Monjuvi, Jakafi, Zynyz |
| Astellas Pharma US INC | $255.04 | 2022-2025 | Padcev, Xtandi, Vyloy |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuma Ndibe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.